Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin
- PMID: 2286588
- DOI: 10.1093/jac/26.suppl_d.137
Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin
Abstract
Preliminary results are presented of an ongoing, prospective, randomized, study comparing ofloxacin, ciprofloxacin and co-trimoxazole/colistin for the prevention of infection in patients with acute leukaemia. The results for 59 patients (median age 47 years, range 21-72) included 88 episodes of neutropenia, each associated with a course of cytotoxic therapy. The main factor measured was the time elapsed from the beginning of neutropenia (neutrophils less than 500/microliter) until the first infectious febrile episode. The median time for the period was 12 days (range 1-56) for the cotrimoxazole/colistin group, 15 days (range 1-38) for the ofloxacin group and 20 days (range 1-36) for the ciprofloxacin group (differences not significant). Microbiologically proven major infections occurred in 10/27 treatment courses with co-trimoxazole/colistin 7/31 courses with ofloxacin and 7/30 courses with ciprofloxacin (P not significant). These were mostly due to Gram-positive cocci. There were no Gram-negative infections in the quinolone groups compared with one major Pseudomonas aeruginosa infection in the co-trimoxazole/colistin group. No Pneumocystis carinii infections were encountered. Adverse reactions associated with co-trimoxazole/colistin required discontinuation of medication in 11/27 treatment courses because of compliance problems, skin reactions or gastrointestinal intolerance. There were significantly fewer discontinuations in the ofloxacin (n = 2) and in the ciprofloxacin groups (n = 3). Major side effects of the quinolones included persistent icterus in one patient receiving ofloxacin and psychiatric symptoms in one patient receiving ciprofloxacin. It is concluded from these data that there were no statistically significant differences between the three treatment groups in respect of the prevention of infection.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group.Eur J Cancer. 1992;28A(4-5):873-8. doi: 10.1016/0959-8049(92)90138-r. Eur J Cancer. 1992. PMID: 1524913 Clinical Trial.
-
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.Support Care Cancer. 2015 May;23(5):1321-9. doi: 10.1007/s00520-015-2621-0. Epub 2015 Jan 24. Support Care Cancer. 2015. PMID: 25617073
-
Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.Antimicrob Agents Chemother. 1990 Feb;34(2):215-8. doi: 10.1128/AAC.34.2.215. Antimicrob Agents Chemother. 1990. PMID: 2327768 Free PMC article. Clinical Trial.
-
Prevention of infection in acute leukemia.Haematol Blood Transfus. 1990;33:525-30. doi: 10.1007/978-3-642-74643-7_94. Haematol Blood Transfus. 1990. PMID: 2108911 Review.
-
Protecting neutropenic patients from bowel-derived organisms.J Hosp Infect. 1991 Sep;19 Suppl C:43-58. doi: 10.1016/0195-6701(91)90167-7. J Hosp Infect. 1991. PMID: 1684195 Review.
Cited by
-
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.Drugs. 1991 Nov;42(5):825-76. doi: 10.2165/00003495-199142050-00008. Drugs. 1991. PMID: 1723377 Review.
-
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.Antimicrob Agents Chemother. 1994 Apr;38(4):681-7. doi: 10.1128/AAC.38.4.681. Antimicrob Agents Chemother. 1994. PMID: 8031031 Free PMC article.
-
Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.Support Care Cancer. 1996 Sep;4(5):364-9. doi: 10.1007/BF01788843. Support Care Cancer. 1996. PMID: 8883230
-
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010. Drugs. 1996. PMID: 8736621 Review.
-
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD004386. doi: 10.1002/14651858.CD004386.pub3. Cochrane Database Syst Rev. 2012. PMID: 22258955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical